oppn parties Sub-Standard Drugs: India Must Take Strict Action

News Snippets

  • 2nd ODI: Rohit Sharma roars back to form with a scintillating ton as India beat England by 4 wickets in a high scoring match in Cuttack
  • Supreme Court will appoint an observer for the mayoral poll in Chandigarh
  • Government makes it compulsory for plastic carry bag makers to put a QR or barcode with their details on such bags
  • GBS outbreak in Pune leaves 73 ill with 14 on ventilator. GBS is a rare but treatable autoimmune disease
  • Madhya Pradesh government banned sale and consumption of liquor at 19 religious sites including Ujjain and Chitrakoot
  • Odisha emerges at the top in the fiscal health report of states while Haryana is at the bottom
  • JSW Steel net profit takes a massive hit of 70% in Q3
  • Tatas buy 60% stake in Pegatron, the contractor making iPhone's in India
  • Stocks return to negative zone - Sensex sheds 329 points to 76190 and Nifty loses 113 points to 23092
  • Bumrah, Jadeja and Yashasvi Jaiswal make the ICC Test team of the year even as no Indian found a place in the ODI squad
  • India take on England in the second T20 today at Chennai. They lead the 5-match series 1-0
  • Ravindra Jadeja excels in Ranji Trophy, takes 12 wickets in the match as Saurashtra beat Delhi by 10 wickets. All other Team India stars disappoint in the national tournament
  • Madhya Pradesh HC says collectors must not apply NSA "under political pressure and without application of mind"
  • Oxfam charged by CBI over violation of FCRA
  • Indian students in the US have started quitting part-time jobs (which are not legally allowed as per visa rules) over fears of deportation
Manipur Chief Minister Biren Singh resigns after meeting Home Minister Amit Shah and BJP chief J P Nadda /////// President's Rule likely in Manipur
oppn parties
Sub-Standard Drugs: India Must Take Strict Action

By Sunil Garodia
First publised on 2022-12-31 07:54:11

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator.

The position of India as the pharmacy of the world (for supplying generic medicines at low cost) is in danger after two successive incidents of supply of allegedly sub-standard and/or spurious products. Close on the heels of ruckus raised by the death of more than 66 children in Gambia (which was allegedly flagged by WHO without proper preliminary inquiry) by drinking paediatric cough syrups made in India by Haryana-based Maiden Pharmaceuticals which allegedly deed not meet the prescribed standards (an inquiry by the Indian government exonerated the manufacturer of any wrongdoing) comes the allegation from Uzbekistan that many children have died there after consuming cough syrups made and supplied by Noida-based Marion Biotech Private Limited. Drug regulators in India have asked the firm to stop production pending an investigation.

Even though nothing has been heard further about the Gambia case (although one is sure that the Central government is taking it up in all forums), this new case complicates matter further. In addition, data from Central Drugs Standard Control Organization (CDSCO) shows that out of 1487 samples picked up by regulatory agencies from drug manufacturers' facilities across India, 83 or 6% were found to be sub-standard. Greed, and the desire to make extra profits, leads some dirty fish among drug manufacturers to use sub-standard material or play around with accepted formulas to endanger lives. This cannot be allowed. Manufacturers have to adhere to good manufacturing practises (GMP) and ensure that no sub-standard product leaves their manufacturing facilities.

The Indian Pharmaceuticals Alliance and the Central and state governments have a huge role in ensuring this. There should be mandatory random checks of export consignments (in addition to periodic checks at manufacturing facilities). Drug manufacturers and the government have to all to ensure that India pharmaceuticals products meet accepted world standards and there is no deviation to maintain India's place as the prominent drug supplier in the world. Drug manufacturers found indulging in cutting corners should be punished as per law and their licences should be cancelled even if one wilful deviation is detected and the promoters should be blacklisted and denied licence to manufacture pharmaceutical drugs in future.